

Impaired ζ chain expression and IFN- γ production in peripheral blood T and NK cells of patients with advanced lung cancer

LIDIA CISZAK^{1*}, AGATA KOSMACZEWSKA^{1*}, BOZENA WERYNSKA²,
ALEKSANDRA SZTEBLICH¹, RENATA JANKOWSKA² and IRENA FRYDECKA^{1,3}

¹Department of Experimental Therapy, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, 53-114 Wrocław; ²Department of Pulmonology and Lung Cancer, Wrocław Medical University, Grabiszynska 105, 53-439 Wrocław; ³Department of Haematology, Wrocław Medical University, Pasteura 4, 50-367 Wrocław, Poland

Received July 29, 2008; Accepted September 1, 2008

DOI: 10.3892/or_00000205

Abstract. Recent studies show that low expression of ζ chain in T and NK cell leads to impaired anti-tumour immunity in patients with cancer, poor prognosis, and shorter overall survival. Therefore, monitoring ζ chain expression may be useful in assessing immune competence in lung cancer patients and in following changes during anticancer therapies. Such studies concerning small-cell and non-small cell lung cancer (SCLC and NSCLC, respectively) have not been published so far. The expression of ζ chain and IFN- γ in peripheral blood (PB) T and NK cells from SCLC and NSCLC patients at advanced (III, IV) stages were analysed before and after chemotherapy with etoposide and cisplatin using flow cytometry. Serum concentrations of TGF- β 1 and IL-10 were also estimated at each time point tested. Before therapy, impaired ζ chain expression was observed in all the patients corresponding with increased levels of immuno-suppressive cytokines in sera compared with controls. Decreased IFN- γ production in T cells from all patients was also demonstrated. In NK cells, IFN- γ was secreted at lower levels in NSCLC patients, while in the SCLC group it was normal. After chemotherapy, restoration of ζ expression in NK cells and its insignificant increase in T cells in SCLC patents corresponding with normalization of TGF- β secretion were noted. In contrast, NSCLC patients retained impaired ζ expression in T and NK cells. SCLC and NSCLC patients showed a profound defect

in IFN- γ secretion in T and NK cells upon treatment. There were no differences in studied parameters between NSCLC and SCLC groups before and after chemotherapy. This is the first report of impaired ζ expression in PB T and NK cells in patients with SCLC and NSCLC in advanced stages, which may result from higher levels of immunosuppressive cytokines in sera. After cytostatic treatment, all the studied patients, including those with initial good response to chemotherapy, remained with profound abnormalities in T and NK cells, which could have dramatic consequences regarding severely impaired anti-tumour immunity.

Introduction

Several dysfunctions of tumour-infiltrating as well as peripheral blood T lymphocytes and NK cells have been described in patients with cancer. These include abnormalities in signalling via the T-cell receptor (TCR) in T cells and low-affinity Fc receptor for IgG (Fc γ RIII, also known as CD16) in NK cells (1,2), decreased tyrosine kinase activity following triggering with anti-CD3 or anti-CD16 monoclonal antibodies (1,2), reduced or absent Ca²⁺ flux (2), poor proliferative responses (1,3-6), defects in lytic capacity (5), decreased ability to cytokine production (1,7-9), and increased propensity for spontaneous apoptosis (6,10,11). These significant functional defects in many cases have been correlated with decreased expression of the ζ chain (1-4,6-9).

The ζ chain is a 16-kDa molecule expressed in T lymphocytes as well as NK cells. In T lymphocytes it is a component of the T-cell receptor (TCR), whereas in NK cells it is a part of the activating receptors NK-cell protein 46 (Nkp46), Nkp30, and the Fc γ RIII (12). The ζ chain plays a key role in the transduction of activation signals in T and NK cells. Reduced levels of the ζ chain result in a relative lack of tyrosine residues for phosphorylation and impaired recruitment and phosphorylation of downstream signal-transducing molecules, leading to failure of T- and NK-cell activation, proliferation, and cytokine production (12,13).

Studies in our and other laboratories showed decreased expression of the ζ chain in the tumour-infiltrating and peripheral T lymphocytes and NK cells isolated from

Correspondence to: Dr Lidia Ciszak, Department of Experimental Therapy, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, 53-114 Wrocław, Poland
E-mail: ciszak@iitd.pan.wroc.pl

*Contributed equally

Key words: small cell lung cancer, non-small cell lung cancer, ζ chain, IFN- γ , chemotherapy, T cells, NK cells

patients with various types of solid tumours (1,3-10,14-28) and haematological malignancies (29-31). Moreover, it has been observed that low expression of the ζ chain is associated with more advanced stage of tumour and poor clinical outcome (9,22). Based on these findings it has been suggested that low expression of the ζ chain in T and NK cell leads to impaired anti-tumour immunity in patients with cancer, poorer prognosis, and shorter overall survival and that ζ chain expression in these cells may be a putative biomarker of prognosis (9,22,33).

Lung cancer remains a major cause of malignancy-related death in many countries because of its frequency, its detection at advanced stages of disease (III and IV), and its relative resistance to currently available chemotherapy and radiation therapy (34). Lung cancers are divided histologically into two major groups: small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (34,35). SCLC represents 15-20% of lung cancer cases and is a very aggressive disease characterised by rapid tumour growth, early development of widespread metastases, and overall poor prognosis despite its sensitivity to chemotherapy and radiation (34,35). Long-term survival of patients with SCLC is rare, since only 20-40% of patients with limited disease and <5% of patients with extensive disease are alive 2 years after diagnosis (36). NSCLC affects ~80% of lung cancer patients (34,35). In contrast to SCLC patients, response of NSCLC patients to chemotherapy is low (34). The median survival for advanced NSCLC patients without cytotoxic treatment is <6 months (37), which extends to ~8-10 months for treated patients (34). Therefore, a better understanding of the molecular biology of SCLC and NSCLC may be useful in identifying new targets for drug development that should help improve therapeutic options and patient outcomes.

Little information is available on the ζ chain expression in tumour-infiltrating and peripheral blood (PB) lymphocytes isolated from patients with lung cancer. Woo *et al* (32) examined the expression of this molecule in tumour-infiltrating and PB T cells from 9 patients with NSCLC at early stages of disease. Detailed information on the ζ chain expression in patients with SCLC and with NSCLC at advanced stages of disease is lacking so far.

Since the ζ chain is considered a putative biomarker of immune function and survival, and only limited data are available concerning its expression in lung cancer patients, we undertook the present study to evaluate the expression of the ζ chain in freshly isolated PB T (CD3⁺) and NK (CD3⁻/CD56⁺) lymphocytes from patients with SCLC and NSCLC at advanced stages (III and IV) of disease in comparison with healthy individuals. We also sought to determine whether ζ chain expression differs in SCLC and NSCLC patients. We gave special attention to evaluating the effects of chemotherapeutic treatment of lung cancer patients on the ζ chain expression. Additionally, we examined the capability of T and NK PB cells from the two groups of lung cancer patients to produce IFN- γ and the obtained results were compared with those of corresponding cells from healthy controls. We also aimed to determine the possible prognostic significance of ζ chain expression and IFN- γ production on the survival of the patients with SCLC and NSCLC.

Table I. Characteristics of patients.

Characteristics	SCLC	NSCLC
Number	15	32
Age (years)		
Mean	59	62
Range	43-81	47-78
Gender		
Male	9	17
Female	6	15
Performance status (ECOG)		
0	1	1
1	9	14
2	3	15
3	2	2
Stage		
LD	8	III A-B: 10
ED	7	IV: 22
Smoking		
Non-smoker	0	4
Smoker	15	28
Weight loss (>5%)		
No	13	17
Yes	2	15
Chronic obstructive pulmonary disease (COPD)		
No	11	24
Yes	4	8
Chemotherapy response		
Complete or partial response	7	9
Stable or progressive disease	8	23

Patients and methods

Patient characteristics. Peripheral blood samples were obtained after informed consent from 15 patients with histologically confirmed SCLC, 32 patients diagnosed with NSCLC, and 17 age- and gender-matched healthy volunteers. The patient characteristics are listed in Table I. Each patient underwent the following staging procedures: physical examination, chest radiograph, computed tomography (CT) of the chest and upper abdomen, brain CT, and hematologic and biochemical procedures. SCLC and NSCLC patients received etoposide (100 mg/m²) and cisplatin (25 mg/m²) on days 1-3. Chemotherapy was repeated every 3 weeks. Six and four cycles of therapy were administered to the patients with SCLC and NSCLC, respectively. Blood samples were taken twice from patients: at the time of diagnosis and again after chemotherapeutic treatment.

Table II. Mean percentages (and standard error) of peripheral blood CD3⁺ and CD3⁺/CD56⁺ lymphocytes expressing the ζ chain and IFN- γ in all studied groups.

	CD3 ⁺ / ζ ⁺	CD3 ⁺ /CD56 ⁺ / ζ ⁺	CD3 ⁺ /IFN- γ ⁺	CD3 ⁺ /CD56 ⁺ /IFN- γ ⁺
SCLC (n=15)				
Before chemotherapy	26.99 (4.65)	37.85 (4.58)	8.2 (1.53)	13.92 (3.07)
After chemotherapy	40.93 (4.23)	56.43 (6.85)	4.25 (0.86)	8.79 (1.37)
	NS	P<0.0001	P=0.01	P=0.03
NSCLC (n=32)				
Before chemotherapy	30.05 (5.53)	45.09 (5.53)	6.19 (1.00)	9.57 (1.65)
After chemotherapy	31.51 (5.48)	41.05 (5.75)	7.63 (1.97)	5.63 (0.85)
	NS	NS	P=0.01	P=0.03
Control group (n=15)	75.12 (2.73)	65.54 (2.93)	9.90 (0.92)	19.21 (2.45)
SCLC vs. NSCLC				
Before chemotherapy	NS	NS	NS	NS
After chemotherapy	NS	NS	NS	NS
SCLC vs. Control group				
Before chemotherapy	P<0.0001	P<0.0001	P=0.05	NS
After chemotherapy	P<0.0001	NS	P<0.0001	P=0.0008
NSCLC vs. Control group				
Before chemotherapy	P<0.0001	P<0.0001	P=0.01	P=0.008
After chemotherapy	P<0.0001	P=0.002	P=0.0001	P<0.0001

Cell isolation. Peripheral blood mononuclear cells (PBMCs) were separated by buoyant density-gradient centrifugation on Lymphoflot (Biotest, Germany) from freshly drawn peripheral venous blood and washed 3 times in 0.9% saline.

The ζ chain staining and flow cytometric analysis. The experiments on fresh cells were carried out by double and triple labelling with anti-CD3/RPE, anti-CD3/PerCP, and anti-CD56/RPE monoclonal antibodies (MoAbs) (Becton Dickinson, San Jose, CA, USA) and anti-CD247/FITC MoAb (Serotec) directed against the cytoplasmic domain of the ζ chain.

Briefly, after isolation the cells were washed twice in phosphate-buffered saline (PBS) (without Ca²⁺ and Mg²⁺), divided into tubes at a concentration of 5x10⁵ cells per tube, stained with anti-CD3/RPE MoAb (for detection of the ζ chain in T cells) or anti-CD3/PerCP and anti-CD56/RPE MoAbs (for detection of the ζ chain in NK cells) and incubated for 30 min at 4°C in the dark. Excess unbound antibodies were removed by two washes with PBS. Following these washes, the cells were fixed and permeabilized with 2% paraformaldehyde and the BD Permeabilizing Solution 2 (Perm 2) (Becton Dickinson) according to the manufacturer's instructions. For the detection of the cytoplasmic domain of the ζ chain, cells were incubated for 30 min at 4°C in the dark with AB serum and anti-CD247(the ζ chain)/FITC MoAb, then washed twice in PBS, resuspended in PBS, and analysed by flow cytometry using a FACScalibur flow cytometer (Becton Dickinson). Negative controls were always done by

omitting the MoAb and by incubating the cells with mouse Ig of the same isotype as the MoAbs conjugated with FITC, PerCP or RPE. The results were expressed as the proportion of double-positive cells. At least 10,000 events per sample were analysed.

Culture conditions and intracellular IFN- γ staining. Cells (2x10⁶/ml) were cultured in RPMI-1640 medium (Gibco, Paisley, UK) supplemented with 10% foetal calf serum (Flow Laboratories, UK), 2 mmol/l L-glutamine, and 50 μ g/ml gentamycin (Gibco). In order to evaluate intracellular IFN- γ expression, cells were incubated with 25 ng/ml of PMA and 1 μ g/ml of ionomycin (Ion) for 4 h at 37°C in a 5% CO₂ atmosphere. Cytokine secretion was blocked with 10 μ g/ml of brefeldin A (BFA), a protein transport inhibitor. Furthermore, this procedure was performed on non-activated lymphocytes using only BFA to assess the level of residual IFN- γ synthesis from *in vivo* activation. Cultured cells were washed twice in PBS, divided into tubes at a concentration of 5x10⁵ cells per tube, stained with anti-CD3/FITC or anti-CD3/PerCP and anti-CD56/FITC MoAbs (Becton Dickinson), and incubated for 20 min at room temperature. Following membrane staining, the cells were then fixed and permeabilized with the BD Permeabilizing Solution 2 (Perm 2) (Becton Dickinson) according to the manufacturer's instructions. Then the cells were incubated with anti-IFN- γ /RPE MoAb (PharMingen, San Diego, CA, USA) or IgG1 isotypic control. Finally, the cells were washed and analysed by flow cytometry directly after preparation.




Figure 1. Representative data of the ζ chain expression (open histograms) in peripheral blood CD3⁺ (Panel I) and CD3⁺/CD56⁺ (Panel II) cells from patients with SCLC and NSCLC before (A) and after chemotherapy (B), and from healthy individuals. The grey histograms represent the isotype controls. The numbers located on the histograms represent the percentages of CD3⁺ (Panel I) and CD3⁺/CD56⁺ (Panel II) cells co-expressing the ζ chain.

Assessment of TGF- β 1 and IL-10 concentrations. Serum samples collected from all patients with SCLC and NSCLC were stored frozen (-70°C) until analysed. Serum TGF- β 1 and IL-10 concentrations were determined by enzyme-linked immunosorbent assay (ELISA) using a R&D Systems reagent kit (UK) according to the manufacturer's recommendations. Each sample was run in duplicate. The assay range is 7.8-500 pg/ml for IL-10 and 31.2-2000 pg/ml for TGF- β 1.

Statistical analysis. Repeated-measures one-factor analysis of variance (ANOVA) was used to compare all the studied groups with respect to ζ chain expression, IFN- γ production, and TGF- β 1 and IL-10 secretion. Survival was analysed using the Kaplan-Meier method. Survival was defined as the time between a moment of diagnosis and death. If dead had not occurred, survival time was considered censored as the last follow-up time. To study the potential influence of ζ chain expression and IFN- γ production on survival, the Cox's proportional-hazards model was used. Results were considered significant at $P \leq 0.05$.

Results

Expression of the ζ chain in freshly drawn T and NK lymphocytes from patients with SCLC and NSCLC and healthy subjects. We performed intracellular staining for the ζ chain in freshly drawn T (CD3⁺) and NK (CD3⁺/CD56⁺) PB lymphocytes from patients with SCLC or NSCLC and controls. The results, expressed as the mean proportions of CD3⁺/ ζ ⁺ and CD3⁺/CD56⁺/ ζ ⁺ cells, are shown in Table II. We found that the mean percentages of T and NK cells co-expressing the ζ chain in the two groups of patients with lung cancer were significantly lower than the mean frequencies of the corresponding cells from healthy individuals (Fig. 1). Next we compared the studied groups of patients in the context of possible differences in the ζ chain expression. We observed that the mean percentages of CD3⁺/ ζ ⁺ and CD3⁺/CD56⁺/ ζ ⁺ cells did not differ between the patients with SCLC and NSCLC.

Further we analysed the possible influence of chemotherapeutic treatment on ζ chain expression in the patients with lung cancer. We found that in the patients with SCLC,

Table III. Serum TGF- β 1 and IL-10 concentrations (pg/ml) in all studied groups (mean and standard error).

	TGF- β 1	IL-10
SCLC (n=15)		
Before chemotherapy	27995.4 (5458.0)	8.5 (3.9)
After chemotherapy	18750.9 (4656.9)	2.6 (0.9)
	NS	NS
NSCLC (n=32)		
Before chemotherapy	36839.9 (7719.6)	5.4 (2.2)
After chemotherapy	26894.5 (4911.2)	9.3 (3.1)
	NS	NS
Control group (n=15)	15318.6 (3976.8)	0.8 (0.6)
SCLC vs. NSCLC		
Before chemotherapy	NS	NS
After chemotherapy	NS	NS
SCLC vs. Control group		
Before chemotherapy	P=0.04	P=0.02
After chemotherapy	NS	P=0.03
NSCLC vs. Control group		
Before chemotherapy	P=0.008	P=0.009
After chemotherapy	P=0.04	P=0.001

chemotherapy resulted in an increase in the mean frequencies of CD3 $^+$ / ζ $^+$ as well as CD3 $^+$ /CD56 $^+$ / ζ $^+$ cells, but this increment was statistically significant only in case of CD3 $^+$ /CD56 $^+$ / ζ $^+$ lymphocytes, reaching the same level as that of controls. In patients with NSCLC, no significant effect of chemotherapeutic treatment on ζ chain expression was seen. In this group of patients the mean percentages of CD3 $^+$ / ζ $^+$ and CD3 $^+$ /CD56 $^+$ / ζ $^+$ cells remained markedly lower compared with the mean frequencies of the corresponding cells from healthy volunteers. Moreover, after chemotherapy the mean proportions of CD3 $^+$ and CD3 $^+$ /CD56 $^+$ lymphocytes co-expressing the ζ chain did not differ between the patients with SCLC and NSCLC.

IFN- γ production in freshly drawn T and NK cells from patients with SCLC and NSCLC and healthy subject. To find out whether decreased ζ chain expression influences the functions of T and NK lymphocytes from patients with lung cancer, we performed functional studies by measuring IFN- γ production in these cells and the results were compared with the values found in healthy subjects. The mean percentages of CD3 $^+$ /IFN- γ $^+$ and CD3 $^+$ /CD56 $^+$ /IFN- γ $^+$ lymphocytes are shown in Table II. We observed that in patients with SCLC the mean proportion of CD3 $^+$ /IFN- γ $^+$ cells was markedly lower than in healthy individuals, whereas the mean frequency of CD3 $^+$ /CD56 $^+$ /IFN- γ $^+$ cells was comparable to the value found in the controls (Fig. 2). In patients with NSCLC the mean percentages of T and NK lymphocytes producing IFN- γ were significantly lower than in the healthy subjects. No significant differences in the

mean proportions of CD3 $^+$ /IFN- γ $^+$ and CD3 $^+$ /CD56 $^+$ / γ $^+$ cells were found between the patients with SCLC and NSCLC.

Furthermore, we tested the possible effect of chemotherapeutic treatment on IFN- γ synthesis. We found that in patients with SCLC the chemotherapy resulted in marked decreases in the mean frequencies of CD3 $^+$ /IFN- γ $^+$ as well as CD3 $^+$ /CD56 $^+$ /IFN- γ $^+$ cells. In patients with NSCLC the mean percentage of CD3 $^+$ lymphocytes producing IFN- γ significantly increased after chemotherapeutic treatment, whereas the mean proportion of CD3 $^+$ /CD56 $^+$ /IFN- γ $^+$ cells markedly decreased. The mean frequencies of T and NK lymphocytes co-expressing IFN- γ in patients with SCLC and NSCLC after chemotherapy were comparable and remained significantly lower compared with those of controls.

The levels of TGF- β 1 and IL-10 in the sera of the patients with SCLC and NSCLC and healthy subjects. To explain whether the decrease in ζ chain expression and IFN- γ production in the group of lung cancer patients may be related to the presence of immunosuppressive cytokines such as TGF- β 1 and IL-10 in the microenvironment, we measured the levels of these cytokines in the sera of the lung cancer patients at the time of diagnosis and again after chemotherapeutic treatment and the results were compared with the values found in the healthy volunteers. The results are shown in Table III. We observed that the patients with SCLC and NSCLC had significantly higher median levels of TGF- β 1 and IL-10 in their sera before chemotherapy than the healthy individuals. In the patients with SCLC,




Figure 2. Cytometric presentation of IFN- γ expression (open histograms) by CD3 $^{+}$ (Panel I) and CD3 $^{+}$ /CD56 $^{+}$ (Panel II) lymphocytes from patients SCLC and NSCLC before (A) and after chemotherapeutic treatment (B), and from healthy individuals. The grey histograms represent the isotype controls. The numbers located on the histograms represent the percentages of CD3 $^{+}$ (Panel I) and CD3 $^{+}$ /CD56 $^{+}$ (Panel II) cells co-expressing the IFN- γ .

chemotherapeutic treatment resulted in a decrease in median levels of TGF- β 1 and IL-10, but only TGF- β 1 reached the levels found in the healthy volunteers.

The therapy in NSCLC patients decreased the levels of TGF- β 1. In contrast, IL-10 was produced at even higher amounts. However, these differences were not statistically significant compared with pre-treatment levels. In consequence, the mean concentrations of the studied cytokines in the patients with NSCLC after chemotherapy remained markedly higher than in the controls. No significant differences in the levels of TGF- β 1 and IL-10 in the sera were found among the patients with SCLC and NSCLC before and after chemotherapy.

ζ chain expression and IFN- γ production in T and NK cells with regard to response to chemotherapy in the groups of patients with SCLC and NSCLC. We also aimed to determine whether there is an association between ζ chain expression and IFN- γ production and effectiveness of chemotherapy in patients with SCLC and NSCLC. Based on the clinical data of the effect of chemotherapy, we divided the two groups of SCLC and NSCLC patients into responders, who reached partial or complete remissions of tumour upon chemotherapy,

and non-responders, with stable or even increased tumour load after chemotherapeutic treatment. Next we analysed the changes in ζ chain expression and IFN- γ production after chemotherapy.

Among the patients with SCLC, in the responders the mean percentages of CD3 $^{+}$ / ζ $^{+}$ cells increased in 6 of the 7 patients (to 335.7, 909.9, 130.6, 122.8, 185.5, and 116.6%) and decreased in 1 individual (to 79.5%) compared with the values before therapy (Fig. 3A). The mean proportions of CD3 $^{+}$ cells co-expressing the ζ chain increased in 2 of the 4 non-responders (to 111.8 and 199.7%) and remained essentially unchanged in other 2 (to 96.2, and 106.2%) (Fig. 3B). The mean frequencies of CD3 $^{+}$ /CD56 $^{+}$ / ζ $^{+}$ lymphocytes increased in 5 of the 7 responders (to 169.2, 181.1, 207.2, 147.1, 162.0%), remained essentially unchanged in 1 (to 90.7%) and decreased in 1 (to 66.0%) (Fig. 3A), whereas the mean percentages of these lymphocytes increased in all the non-responders (to 218.6, 117.4, 132.0, 317.0%) (Fig. 3B).

The mean proportions of CD3 $^{+}$ cells co-expressing IFN- γ increased in 1 of the 7 responders (to 133.8%), remained unchanged in 1 (102.7%), and decreased in 5 (to 15.2, 41.9, 4.1, 45.8, and 89.0%) (Fig. 3A). In non-responders, the




Figure 3. The changes in ζ chain and IFN- γ expression in peripheral blood T and NK cells from patients with SCLC after effective (A) or ineffective chemotherapy (B). The change >10% was considered as significant.

mean frequencies of CD3⁺/IFN- γ ⁺ cells increased in 1 of the 4 (to 114.5%) and decreased in 3 (to 29.0, 22.5, and 35.6%) (Fig. 3B). The mean percentages of NK lymphocytes co-expressing IFN- γ increased in 2 of the 7 responders (to 110.1 and 250.5%), remained essentially unchanged in

1 (to 107.3%), and decreased in 4 (to 24.1, 39.7, 38.5, and 7.3%) (Fig. 3A), whereas the mean proportions of these lymphocytes increased in 2 of the 4 non-responders (to 213.9 and 160.6%) and decreased in the other 2 (to 32.5 and 18.4%) (Fig. 3B).




Figure 4. The changes in ζ chain and IFN- γ expression in peripheral blood T and NK cells from patients with NSCLC after effective (A) or ineffective chemotherapy (B). The change >10% was considered as significant.

Among the NSCLC patients, the mean frequencies of CD3⁺/ ζ ⁺ cells increased in 5 of the 9 responders (to 253.2, 189.8, 289.5, 212.6, and 193.3%), remained unchanged in 1 (93.5%), and decreased in 3 (to 21.9, 57.9, and 49.8%)

(Fig. 4A). In contrast, the mean percentages of CD3⁺ cells co-expressing the ζ chain increased in only 4 of the 14 in non-responders (to 207.8, 246.3, 337.8, and 130.8%), remained unchanged in 2 (106.2 and 103.5%), and decreased in 8 (to

65.3, 76.8, 65.1, 43.9, 42.5, 77.6, 39.7, and 67.9%) (Fig. 4B). The mean percentages of CD3⁺/CD56⁺/ ζ ⁺ lymphocytes increased in 7 of the 9 responders (to 122.1, 223.0, 126.2, 110.5, 209.2, 117.0, and 314.4%), remained essentially unchanged in 1 (95.4%), and decreased in 1 (to 10.6%), whereas in non-responders the mean proportions of these lymphocytes increased only in 4 of the 14 (to 435.7, 157.2, 115.3, 160.7%), remained unchanged in 2 (to 105.5% and 100.6%), and decreased in 8 (to 70.1, 63.2, 30.8, 49.6, 79.1, 36.3, 59.0, and 61.4%).

The mean proportions of CD3⁺ cells co-expressing IFN- γ increased in 4 of the 9 responders (to 303.4, 561.8, 1880.0, and 1100.0%) and decreased in 5 (to 80.4, 91.3, 30.7, 62.9, and 32.3%) (Fig. 4A). In contrast, the mean frequencies of CD3⁺/IFN- γ ⁺ cells increased in 7 of the 13 non-responders (to 160.9, 218.1, 342.6, 272.4, 130.2, 178.6, and 177.9%) and decreased in 6 (to 71.8, 77.6, 53.6, 55.0, 52.5, and 36.1%). The mean percentages of CD3⁺/CD56⁺/IFN- γ ⁺ lymphocytes increased in 3 of the 9 responders (to 142.6, 1140.0, and 791.6%), remained unchanged in 1 (96.6%), and decreased in 5 (to 29.6, 36.4, 32.4, 33.6, and 52.2%), whereas in non-responders the mean proportions of these lymphocytes increased in 6 of the 12 (to 288.8, 229.7, 210.5, 114.7, 125.6, and 285.2%), remained unchanged in 1 (104.3%), and decreased in 5 (to 73.8, 57.2, 84.4, 55.9, and 23.8%) (Fig. 4A and B).

Correlations between ζ chain expression, IFN- γ production, and TGF- β 1 and IL-10 serum levels in lung cancer patients. We analysed the correlations of ζ chain expression, IFN- γ production, and TGF- β 1 and IL-10 serum levels among themselves in all the studied groups of lung cancer patients. No correlations were found.

ζ chain expression, INF- γ production, and survival analysis. Next we aimed to determine the possible prognostic significance of ζ chain expression and IFN- γ production on survival of the patients with SCLC and with NSCLC. No significant impact of ζ chain expression on survival of the patients with SCLC or those with NSCLC was seen. Similarly, there was no association between survival probability and the median proportion of T or NK lymphocytes co-expressing IFN- γ in the two groups of lung cancer patients.

Discussion

Due to the key role of the ζ chain in the transduction of signals delivered via the receptors of T and NK cells, reduced expression of this molecule impairs T and NK cell signalling and contributes to immune cell dysfunction. Therefore, monitoring the ζ chain expression is useful in assessing immune competence in patients with cancer and in following changes in immune competence during anticancer therapies (33). To the best of our knowledge, such a study concerning lung cancer patients has not been published so far. We found that the mean proportions of T and NK cells co-expressing the ζ chain in patients with SCLC and NSCLC before chemotherapy were significantly lower than the mean frequencies of the corresponding cells

from healthy volunteers. There is a discrepancy between our results and data shown by Woo *et al* (32). The authors did not observe decreased expression of ζ chain in tumour-infiltrating or PB T cells isolated from patients with NSCLC. This discrepancy may result from the fact that Woo *et al* (32) investigated patients with NSCLC at early stages of disease only, whereas we performed the studies in patients at advanced stages of disease. In the light of recent findings, decreased expression of ζ chain in PB lymphocytes is observed in patients with advanced, but not early stages of disease (9,18,22,32). Our results also showed that the level of ζ chain expression did not depend on the histological form of the lung cancer, since the mean frequencies of CD3⁺/ ζ ⁺ and CD3⁺/CD56⁺/ ζ ⁺ cells in SCLC and NSCLC patients were comparable.

An interesting question was whether chemotherapeutic treatment with cisplatin and etoposide, the combination of drugs commonly used in the therapy of lung cancer patients, leads to restoration of ζ chain expression in these patients, since recent studies showed that normalization of the ζ chain expression in PB lymphocytes following therapy may be a good prognostic sign (33). We showed that in patients with SCLC, the chemotherapeutic treatment resulted in the normalization of ζ chain expression only in PB NK cells, while the increase in ζ chain expression in T cells, although substantial, was not statistically significant. Moreover, the tendency to up-regulate the ζ chain was more profound among the SCLC patients with good response to cytostatic treatment, while ζ chain expression usually remained unchanged in the non-responding patients. In contrast, no treatment-related modification of ζ chain expression was observed in the patients with NSCLC. These findings suggest that only the patients with SCLC have a potential to up-regulate ζ chain expression after cytostatic treatment. The frequency of tumour regression was higher in the group of patients with SCLC.

It was recently suggested that one of the mechanisms responsible for low ζ chain expression in patients with various forms of cancer may be the secretion of immunosuppressive cytokines by tumour cells. Many malignant cells, including SCLC and NSCLC, and/or stromal cells produce TGF- β 1 and IL-10 (38-41) and, more importantly, the elevated serum levels of these cytokines have been correlated with decreased expression of the ζ chain (24). Recent studies show that high concentrations of TGF- β 1 and IL-10 in sera are usually associated with tumour progression and poor response to immunotherapy (38,42). Our study confirmed previous data (39-41) that before chemotherapy SCLC and NSCLC patients had higher serum levels of TGF- β 1 and IL-10 compared with healthy volunteers. Thus it seems possible that the decreased mean proportions of CD3⁺/ ζ ⁺ and CD3⁺/CD56⁺/ ζ ⁺ PB cells from patients with SCLC and NSCLC may result from the immunosuppressive activity of TGF- β 1 and IL-10 in the microenvironment. It is of note that in the group of SCLC patients, chemotherapeutic treatment resulted in decreases in serum levels of TGF- β 1 to the levels found in healthy volunteers, which corresponded with the normalization of ζ chain expression in NK cells and its insignificantly up-regulation in T lymphocytes. It is possible, therefore, that

the increase in ζ chain expression observed in SCLC patients may result, at least in part, from normalization of the levels of immunosuppressive cytokines in the sera of these patients. However, the treatment did not normalize the levels of IL-10 in SCLC patients or the levels of the two immunosuppressive cytokines in NSCLC patients, suggesting that lung cancer patients maintained immunosuppression despite the cytostatic treatment.

Since the down-regulation of the ζ chain expression in T and NK cells leads to functional impairment of these lymphocytes, we were also interested in assessing the intracellular production of IFN- γ in T and NK cells from SCLC and NSCLC patients. Recent studies demonstrated significantly lower amounts of IFN- γ in whole blood cell cultures from the two groups of lung cancer patients compared with healthy individuals (43-46). Intracellular staining of IFN- γ in T lymphocytes showed that the proportion of CD3⁺/IFN- γ ⁺ cells was also lower in lung cancer patients compared with controls, although the differences were not statistically significant, probably due to the high variability even in the healthy volunteers (46). Additionally, no significant differences between SCLC and NSCLC patients in the levels of IFN- γ secretion were found (45). Our findings are in agreement with these studies. The production of IFN- γ by CD3⁺ cells from SCLC patients and CD3⁺ and CD3⁺/CD56⁺ PB lymphocytes from NSCLC patients was significantly suppressed, remaining on comparable levels among the studied patients.

It has been found that TGF- β 1 and IL-10 inhibit the secretion of a variety of cytokines by immunocompetent cells, such as IFN- γ (38,42,43), which is one of the major anti-tumour cytokines (47,48). The mechanisms underlying this process are still not clear. Based on other (38,42,43) and our present findings, it seems that TGF- β 1 and IL-10 secreted at high levels in the sera of patients with SCLC and NSCLC decrease the mean proportions of T and NK cells co-expressing the ζ chain, leading to functional impairment of these cells, including a decrease in IFN- γ production. A recent study confirmed a high frequency of IL-10- and TGF- β -producing T cells corresponding with a low frequency of IFN- γ -secreting T cells in growing tumour in lungs (49). These findings support the observation that T regulatory cells (Treg) secreting IL-10 and TGF- β are recruited/activated in the tumour and, to a lesser degree, in peripheral blood, thus suppressing the development of IFN- γ -producing effector T cells (32,49).

Since chemotherapeutic treatment partially normalizes the expression of ζ chain in SCLC patients, we were also interested in assessing whether chemotherapy leads to reconstitution of suppressed IFN- γ production in T and NK PB lymphocytes from lung cancer patients. Unexpectedly, in patients with SCLC we observed further decreases in the ability to produce IFN- γ by CD3⁺ and CD3⁺/CD56⁺ cells after chemotherapy despite the restoration of ζ chain expression and partial normalization of the immunosuppressive cytokine network in the microenvironment. In addition, we noted a tendency to down-regulate IFN- γ production in SCLC patients with remission as well as with stabilization or progression of the disease. Given the demonstrated severe and long-term impact of chemotherapy

on the number and function of lymphocytes in cancers (46) and the fact that tumour cells from SCLC patients exert relative sensitivity to chemotherapy, we suggest that SCLC cells remained functionally more affected after cytostatic treatment than chemotherapy-resistant NSCLC cells.

In contrast, among the patients with NSCLC we found a high variability in IFN- γ production by T and NK lymphocytes. It is noteworthy, however, that a slightly higher frequency of up-regulated IFN- γ production after treatment was observed among those with no response to chemotherapy compared with patients in remission. Our results are in line with the findings showing that in NSCLC, the presence of tumour cells or tumour-derived factors in PB following tumour growth favours the differentiation of T cells towards tumour-specific Th1 (CD4⁺/IFN- γ ⁺ cells) and Tc1 (CD8⁺/IFN- γ ⁺) (50). A high Th1/Th2 ratio in PB may be a result of tumour-mediated Th1-dominant differentiation in association with tumour-derived substances in PB. Thus a high Th1/Th2 ratio in PB seems to be a negative prognostic factor, especially in advanced stages of NSCLC. The above observation may indicate that among patients with NSCLC, the individuals with increased IFN- γ expression after chemotherapy seem to have a significantly worse prognosis. However, the present study clearly showed that the mean percentage of CD3⁺/IFN- γ ⁺ cells significantly increased after chemotherapy in patients with NSCLC, but this increment did not reach the normal levels, indicating a substantial defect in T-cell responses. It appears that the impaired IFN- γ production may be a characteristic of a compromised tumour status in lung cancer patients and also a result of cytostatic treatment, at least in chemotherapy-sensitive SCLC. The profound impairment in IFN- γ secretion in lung cancer patients could have dramatic consequence, since it is known to be involved in effective anti-tumour immunity, exerting antiproliferative, antiangiogenic, and proapoptotic effects on tumour cells (47,48).

In conclusion, we report here for the first time impaired ζ chain expression in PB T and NK cells in patients with SCLC and NSCLC in advanced stages, which may result from the increased levels of immunosuppressive cytokines in the sera. Our present data thus clearly confirmed cancer-associated immunosuppression in patients with advanced SCLC and NSCLC. We also found that SCLC and NSCLC patients, including individuals with initial good response to chemotherapy, maintained profound abnormalities in T and NK cells after cytostatic treatment. Further studies are therefore needed to develop novel strategies to improve the cellular immune response and achieve long-term survival in lung cancer patients.

Acknowledgements

This work was supported by Wroclaw Medical University (grant: no. 86)

References

1. Lai P, Rabinowich H, Crowley-Nowick P, Bell MC, Mantovani G and Whiteside TL: Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. *Clin Cancer Res* 2: 161-173, 1996.

2. Whiteside TL: Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signalling defects. *Adv Exp Med Biol* 451: 167-171, 1998.
3. Lockhart DC, Chan AK, Mak S, *et al*: Loss of T-cell receptor-CD3 ζ and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma. *Surgery* 129: 749-756, 2001.
4. Healy CG, Simons JW, Carducci MA, DeWeese TL, Bartkowski M, Tong KP and Bolton WE: Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. *Cytometry* 32: 109-119, 1998.
5. Choi SH, Chung EJ, Whang DY, Lee SS, Jang YS and Kim CW: Alteration of signal-transducing molecules in tumor-infiltrating lymphocytes and peripheral blood T lymphocytes from human colorectal carcinoma patients. *Cancer Immunol Immunother* 45: 299-305, 1998.
6. Reichert TE, Strauss L, Wagner EM, Gooding W and Whiteside TL: Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. *Clin Cancer Res* 8: 3137-3145, 2002.
7. Rabinowich H, Suminami Y, Reichert TE, Crowley-Nowick P, Bell M, Edwards R and Whiteside TL: Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. *Int J Cancer* 68: 276-284, 1996.
8. Kono K, Rensing ME, Brandt RMP, *et al*: Decreased expression of signal-transducing ζ chain in peripheral T cells and natural killer cells in patients with cervical cancer. *Clin Cancer Res* 2: 1825-1828, 1996.
9. Zea AH, Curti BD, Longo DL, *et al*: Alterations in T cell receptor and signal transduction molecules in melanoma patients. *Clin Cancer Res* 1: 1327-1335, 1995.
10. Kuss I, Saito T, Johnson JT and Whiteside TL: Clinical significance of decreased ζ chain expression in peripheral blood lymphocytes of patients with head and neck cancer. *Clin Cancer Res* 5: 329-334, 1999.
11. Whiteside TL and Rabinowich H: The role of Fas/FasL in immunosuppression induced by human tumors. *Cancer Immunol Immunother* 46: 175-184, 1998.
12. Biassoni R, Cantoni C, Pende D, *et al*: Human natural killer cell receptors and co-receptors. *Immunol Rev* 181: 203-214, 2001.
13. Pitcher LA and van Oers NSC: T-cell receptor signal transmission: who gives an ITAM? *Trends Immunol* 24: 554-560, 2003.
14. Nakagomi H, Petersson M, Magnusson I, *et al*: Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. *Cancer Res* 53: 5610-5612, 1993.
15. Finke JH, Zea AH, Stanley J, *et al*: Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. *Cancer Res* 53: 5613-5616, 1993.
16. Bukowski RM, Rayman P, Uzzo R, *et al*: Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy. *Clin Cancer Res* 4: 2337-2347, 1998.
17. Pignataro L, Pagani D, Brando B, Sambatoro G, Scarpato B and Corsi MM: Down-regulation of zeta chain and zeta-associated protein 70 (Zap 70) expression in circulating T lymphocytes in laryngeal squamous cell carcinoma. *Anal Quant Cytol Histol* 29: 57-62, 2007.
18. Nieland JD, Loviscek K, Kono K, *et al*: PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCR zeta expression but are functionally impaired. *J Immunother* 21: 317-322, 1998.
19. Matsuda M, Petersson M, Lenkei R, *et al*: Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. *Int J Cancer* 61: 765-772, 1995.
20. Kurt RA, Urban WJ, Smith JW and Schoof DD: Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules. *Int J Cancer* 78: 16-20, 1998.
21. Kono K, Ichihara F, Iizuka H, Sekikawa T and Matsumoto Y: Expression of signal transducing T-cell receptor zeta molecules after adoptive immunotherapy in patients with gastric and colon cancer. *Int J Cancer* 78: 301-305, 1998.
22. Reichert TE, Day R, Wagner EM and Whiteside TL: Absent or low expression of the ζ chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. *Cancer Res* 58: 5344-5347, 1998.
23. Lopez-Santalla M, Krishnan S, Valeri AP, *et al*: Defective CD3 ζ chain expression in Herpesvirus saimiri (HVS)-derived T-cell lines in gastric adenocarcinoma. *Cell Immunol* 238: 113-122, 2005.
24. von Bernstoff W, Voss M, Freichel S, *et al*: Systemic and local immunosuppression in pancreatic cancer patients. *Clin Cancer Res* 7: S925-S932, 2001.
25. Zehbe I, Schmidt M, Maeurer M, Leo C, Höckel M and Pilch H: Different T-cell receptor (TCR) zeta chain expression in cervical cancer and its precursor lesions. *Zentralbl Gynakol* 128: 266-270, 2006.
26. Taylor DD, Edwards RP, Case CR and Gercel-Taylor C: Modulation of CD3-zeta as a marker of clinical response to IL-2 therapy in ovarian cancer patients. *Gynecol Oncol* 94: 54-60, 2004.
27. Schüle JM, Bergkvist L, Håkansson L, Gustafsson B and Håkansson A: CD28 expression in sentinel node biopsies from breast cancer patients in comparison with CD3-zeta chain expression. *J Transl Med* 2: 45, 2004.
28. Shondel SM, Helm CW, Gercel-Taylor C and Taylor DD: Differential expression of T-cell CD3-zeta chains in patients with cervical dysplasia before and after treatment. *Int J Gynecol Cancer* 17: 1278-1282, 2007.
29. Mozaffari F, Hansson L, Kiaii S, Ju X, Rossmann ED, Rabbani H, Mellstedt H and Österborg A: Signaling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage. *Br J Haematol* 124: 315-324, 2004.
30. Frydecka I, Kaczmarek P, Bocko D, Kosmaczewska A, Morilla R and Catovsky D: Expression of signal-transducing zeta chain in peripheral blood T cells and natural killer cells in patients with Hodgkin's disease in different phases of the disease. *Leuk Lymphoma* 35: 545-554, 1999.
31. Frydecka I, Bocko D, Kosmaczewska A, Ciszak L and Morilla R: The effect of peripheral blood lymphocyte stimulation on zeta chain expression and IL-2 production in Hodgkin's disease. *Br J Cancer* 84: 1339-1343, 2001.
32. Woo EY, Chu CS, Goletz T, *et al*: Regulatory CD4⁺CD25⁺ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. *Cancer Res* 61: 4766-4772, 2001.
33. Whiteside TL: Down-regulation of ζ -chain expression in T cells: a biomarker of prognosis in cancer? *Cancer Immunol Immunother* 53: 865-878, 2004.
34. Hoffman PC, Mauer AM and Vokes EE: Lung cancer. *Lancet* 355: 479-485, 2000.
35. Stupp R, Monnerat C, Turrissi III AT, Perry MC and Leyvraz S: Small cell lung cancer: state of the art and future perspectives. *Lung Cancer* 45: 105-117, 2004.
36. Chute JP, Chen T, Feigal E, Simon R and Johnson BE: Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. *J Clin Oncol* 17: 1794-1801, 1999.
37. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. *BMJ* 311: 899-909, 1995.
38. Fischer JR and Lahm H: Validation of molecular and immunological factors with predictive importance in lung cancer. *Lung Cancer* 45: S151-S161, 2004.
39. Fischer H, Lahm H, Schindel M, Drings P and Krammer P: Constitutive secretion of bioactive transforming factor beta 1 by small cell lung cancer cell lines. *Eur J Cancer* 30: 2125-2129, 1994.
40. Saji H, Nakamura H, Awut I, *et al*: Significance of expression of TGF- β in pulmonary metastasis in non-small cell lung cancer tissues. *Ann Thorac Cardiovasc Surg* 9: 295-300, 2003.
41. Huang M, Wang J, Lee P, *et al*: Human non-small cell lung cancer cells express a type 2 cytokine pattern. *Cancer Res* 55: 3847-3853, 1995.
42. Ahmad M, Rees RC and Ali SA: Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. *Cancer Immunol Immunother* 53: 844-854, 2004.
43. Fisher JR, Schindel M, Stein N, Lahm H, Gallati H, Krammer PH and Drings P: Selective suppression of cytokine secretion in patients with small-cell lung cancer. *Ann Oncol* 6: 921-926, 1995.

44. Szopinski J, von Kleist S, Panorska A, Roginska E, Rogala E and Rowinska-Zakrzewska E: Secretion of interleukin-2 (IL-2) and interferon (IFN gamma) in whole blood cell culture stimulated with mitogens in patients with lung neoplasms. *Pneumonol Alergol Pol* 67: 504-510, 1999.
45. Szopinski J, Panorska A, Roginska E, Rogala E and Rowinska-Zakrzewska E: The effect of small cell lung cancer extension on secretion of interleukin-2 (IL-2) and interferon gamma (IFN gamma) in whole blood culture stimulated with mitogens. *Pneumonol Alergol Pol* 69: 26-32, 2001.
46. Cara I, Grigorescu A, Stavaru C, Radu DL, Mogos I, Szegli G and Salageanu A: Evidence for immune defects in breast and lung cancer patients. *Cancer Immunol Immunother* 53: 1146-1152, 2004.
47. Ikeda H, Old LJ and Schreiber RD: The roles of IFN-gamma in protection against tumor development and cancer immuno-editing. *Cytokine Growth Factor Rev* 13: 95-109, 2002.
48. Beatty G and Paterson Y: IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4⁺ T cells requires tumor responsiveness to IFN-gamma. *J Immunol* 166: 2276-2282, 2001.
49. Jarnicki AG, Lysaght J, Todryk S and Mills KHG: Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4⁺ and CD8⁺ regulatory T cells. *J Immunol* 177: 896-904, 2006.
50. Ito N, Suzuki Y, Taniguchi Y, Ishiguro K, Nakamura H and Ohgi S: Prognostic significance of T helper 1 and 2 and T cytotoxic 1 and 2 cells in patients with non-small cell lung cancer. *Anticancer Res* 25: 2027-2032, 2005.